The historical rank and industry rank for Pieris Pharmaceuticals's Equity-to-Asset or its related term are showing as below:
PIRS'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.11 Med: 0.35 Max: 0.92
Current: 0.69
During the past 11 years, the highest Equity to Asset Ratio of Pieris Pharmaceuticals was 0.92. The lowest was 0.11. And the median was 0.35.
PIRS's Equity-to-Asset is ranked better than 53.29% of 1565
companies
in the Biotechnology industry
Industry Median: 0.67
vs PIRS: 0.69
Pieris Pharmaceuticals Equity-to-Asset Historical Data
The historical data trend for Pieris Pharmaceuticals's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pieris Pharmaceuticals's Equity-to-Asset
For the Biotechnology subindustry, Pieris Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pieris Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pieris Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Pieris Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Pieris Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Pieris Pharmaceuticals Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Pieris Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Pieris Pharmaceuticals (Pieris Pharmaceuticals) Business Description
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PIRS has been successfully added to your 